GSK (GSK, Financial) plc has achieved a significant milestone with the approval of its drug Blenrep by the Medicines and Healthcare products Regulatory Agency in the UK. This authorization makes the UK the first country to approve Blenrep for specific treatment protocols in patients with multiple myeloma.
Blenrep is now authorized for use in combination with bortezomib and dexamethasone (BVd) for adults who have previously undergone at least one therapy. Additionally, it’s approved for use alongside pomalidomide and dexamethasone (BPd) for individuals who have been treated with at least one prior therapy, including lenalidomide.
This approval underscores GSK's commitment to providing innovative treatment options for patients with multiple myeloma, offering new hope in the management of this complex condition.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for GSK PLC (GSK, Financial) is $38.89 with a high estimate of $45.00 and a low estimate of $33.96. The average target implies an upside of 8.67% from the current price of $35.79. More detailed estimate data can be found on the GSK PLC (GSK) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, GSK PLC's (GSK, Financial) average brokerage recommendation is currently 2.8, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for GSK PLC (GSK, Financial) in one year is $41.87, suggesting a upside of 17% from the current price of $35.785. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the GSK PLC (GSK) Summary page.
